New drug combo for EGFR lung cancer with brain mets
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (Sacituzumab Tirumotecan) combined with a third-generation EGFR pill, with or without radiation, for people with EGFR-mutant lung cancer that has spread to the brain and has stopped responding to prior targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old
- You must have a type of lung cancer called non-squamous non-small cell lung cancer that has spread (stage 4)
- Your cancer must have one of two specific EGFR mutations: exon 19 deletion or L858R
- You must have taken an EGFR-targeted pill (TKI) before and your cancer got worse while on it
- You must have new or existing brain metastases confirmed by an MRI
- You must be healthy enough to carry out daily activities (ECOG 0 or 1) and have a life expectancy of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This study tests a new drug called sacituzumab tirumotecan (Sac-TMT) combined with radiation to the brain for people with EGFR-mutant lung cancer that has spread to the brain and has grown despite first-line EGFR inhibitor therapy. The goal is to see if this combination can control the brain tumors better.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) for people with a specific type of non-small cell lung cancer that has spread to the brain and has stopped responding to a certain targeted therapy. The goal is to see if this combination can shrink brain tumors and improve outcomes.
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.